1 results match your criteria: "The University of Texas MD Anderson Cancer Center. cjiang@mdanderson.org.[Affiliation]"
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma.
Haematologica
June 2023
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma characterized by frequent relapses. The development of resistance to ibrutinib therapy remains a major challenge in MCL. We previously showed that glutaminolysis is associated with resistance to ibrutinib.
View Article and Find Full Text PDF